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This review describes the wake/sleep symptoms present in Parkinson's disease, and the
role of the pedunculopontine nucleus in these symptoms. The physiology of PPN cells is
important not only because it is a major element of the reticular activating system, but also
because it is a novel target for deep brain stimulation in the treatment of gait and postural
deﬁcits in Parkinson's disease. A greater understanding of the physiology of the target
nuclei within the brainstem and basal ganglia, amassed over the past decades, has enabled
increasingly better patient outcomes from deep brain stimulation for movement disorders.
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There are now over 200 Parkinson's disease (PD) patients
worldwide implanted with stimulating electrodes in the
region of the pedunculopontine nucleus (PPN), which is part
of the reticular activating system (RAS) [1]. This review will
describe the wake/sleep dysregulation present in PD, and theep. Production and Hosti
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modulation of arousal but rather on its inﬂuence on gait
and posture. We will brieﬂy consider the early research
demonstrating the role of the PPN in posture and locomotion.
It is becoming clear that the parameters of stimulation found
to be salutary for the treatment of PD are those that match
the intrinsic properties of PPN neurons. It is worth noting that
stimulation of the region of the PPN dates to the earliestng by Elsevier B.V. This is an open access article under the CC BY-
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with activation of other wake/sleep related areas. Finally, we
will propose a number of measures to help identify possible
effects of PPN DBS on the arousal system. Although PPN DBS
has virtually no negative effects or reported adverse events,
its clinical application needs further investigation. While
most PPN DBS studies focus on movement, few address
changes in wake/sleep regulation.2. Sleep and arousal in Parkinson's disease
(PD)
PD is characterized by a variety of symptoms, which include 3–
7 Hz resting tremor, rigidity, postural and gait abnormalities,
akinesia, and bradykinesia [1]. In addition, a number of other
symptoms are present, including abnormal reﬂexes as well as
higher-level impairments in frontal lobe function and cognition.
Although many of the symptoms are manifested after a
degenerative process has reduced the function of dopaminergic
substantia nigra (SN) neurons below a certain threshold, there
are a number of additional degenerative or functional changes
in such areas as the locus coeruleus, raphe nuclei, basal
forebrain, and frontal cortex [2]. More recently, it has been
found that the degenerative process begins in the glossophar-
yngeal, vagal, and olfactory nerve nuclei, accounting for non-
motor symptoms [3]. The process ascends from these brain-
stem regions to involve the SN and ultimately the cortex. PD
patients also manifest decreased habituation of the blink and
other reﬂexes [4–8], and exhibit anxiety disorder (including
panic attacks) and depression [9–13]. Moreover, cognitive
impairments related to attentional deﬁcits are present [14–17],
and these correlate with decreased frontal lobe glucose utiliza-
tion [15,18–22].
PD patients show sleep disturbances that include disturbed
rapid eye movement (REM) sleep drive (speciﬁcally the presence
of REM sleep during both night and day, along with hallucina-
tions) [23], which may be related to disease severity [Wetter],
decreased slow wave sleep (SWS), frequent awakenings leading
to daytime sleepiness, and insomnia [24–26]. Disrupted sleep
and early morning awakenings are the most common insomnia
symptoms, but PD patients do not appear to have difﬁculty
initiating sleep [27]. Nevertheless, the most frequent sleep
disorder in PD patients was insomnia in over 80% of those
tested [28]. The reader is referred to a recent review on PPN and
insomnia [29]. Another recent review describes sleep changes
observed in animal models of PD [30]. These observations
suggest that the reticular activating system (RAS), especially
the pedunculopontine nucleus (PPN) that is in charge of waking
and REM sleep, is overactive in PD. We carried out a study of the
P50 midlatency auditory evoked potential, which is generated
by PPN projections to the intralaminar thalamus in the human
[31]. The P50 potential is a click stimulus-induced midlatency
auditory evoked response (at a 50–70ms latency) that follows
the brainstem auditory evoked potentials that occur ato10ms
latency, and the primary auditory evoked “Pa” response at a
25ms latency. The P50 potential is as follows: (a) sleep state-
dependent, such that it is present during waking and REM
sleep, but not during SWS, e.g. it is manifested during arousal
states when PPN is active, (b) blocked by low doses ofscopolamine, e.g. it is generated by cholinergic projections of
the PPN, and (c) rapidly habituating, e.g. reticular in origin with
low synaptic security [31]. Animal studies showed that lesions
of the PPN or injections of inhibitory agents into the PPN
eliminated the equivalent vertex-recorded potential (P13 in
the rodent, “wave a” in the feline), emphasizing the origin of
the waveform as the PPN [31]. In summary, the P50 potential is
an arousal-related waveform in the human.
We showed that the amplitude of the ﬁrst P50 potential
response of a pair of stimuli administered 250ms apart was 40%
higher in PD patients [32]. This suggests an increase in arousal to
phasic stimuli in this disease. Moreover, P50 potential habitua-
tion (the amplitude of the second response as a percent of the
ﬁrst response of a pair) decreased signiﬁcantly in the PD group as
a whole. In addition, there was a statistically signiﬁcant decrease
in habituation with severity. This suggests a deﬁcit in sensory
gating in the disorder. We also measured the P50 potential in PD
patients who received bilateral pallidotomy that alleviated their
motor symptoms, and found that the amplitude and habituation
of the P50 potential was within normal levels [33]. Fig. 1 (left side)
shows the effects of PD on the habituation of the P50 potential as
the disorder advances from stages 3 to 4. The percent habitua-
tion at the 250ms and 500ms interstimulus intervals in age- and
gender-matched controls was similar to patients at stage 3, but
they both differed from patients in stage 4 at the 250ms
interstimulus interval, and from those in stage 5 at both the
250ms and 500ms intervals. That is, the sensory gating deﬁcit
increased with clinical stage.
Fig. 1 (Right side) shows that the percent habituation in stage
5 patients differed from controls at the 250ms and 500ms
intervals, but was restored to control levels by bilateral pallidot-
omy. We speculated that the increased PPN output in PD was
instantly re-inhibited or down regulated by the surgery to
normalize sensory gating and hyperarousal to phasic inputs
[33]. The importance of these results is that there is an
immediate effect by the therapy in reinstituting a balance of
activity. The damage to the SN apparently induces a disturbance
that can be corrected by additional damage (pallidotomy) [33].
One conclusion is that the symptoms involved can be alleviated
almost instantly by appropriate treatment, not requiring
extended reorganization or regeneration, etc. Since lesion of a
region provides little ﬂexibility in the approach, a therapeutic
strategy that can be modiﬁed with changes in status, for
instance, as the disease progresses, would be more desirable.
Prior to the use of L-DOPA for the treatment of PD, lesions of
the thalamus and pallidum were being used, but pharmaco-
logical treatment became the preferred form of therapy [34].
While the use of L-DOPA has been effective for some of the
symptoms of the disease, long-term use (45 years) and
increasing dosages can lead to dyskinesias. Other agents have
been used but they provide less effective relief and can
produce unwanted side effects. Surgical treatment includes
the use of thalamotomy, pallidotomy, and subthalamic
nucleus lesions. Nowadays, the most common therapeutic
approach involves deep brain stimulation (DBS), with the most
common site used being the subthalamic nucleus (STN).
However, DBS of the PPN is now being used for the
treatment of PD.
Fig. 1 – The P50 potential in PD. Left. Paired click stimuli were delivered at three interstimulus intervals (ISI), 250 ms, 500 ms,
and 1000 ms, so that a recovery curve could be plotted. Age- and gender-matched control subjects (black squares) showed
20%, 30%, and 60% habituation of the second response, respectively. PD patients at stage 3 (red circles) showed 30%, 50%,
and 75% habituation, correspondingly, and were not different from controls. Stage 4 patients showed 50%, 75%, and 80%
correspondingly, and differed from controls at the 250 msec ISI. Stage 5 patients showed decreased habituation at 73%, 76%,
and 95%, correspondingly. Stage 5 patients differed signiﬁcantly from control subjects at the 250 ms (**po0.01), and 500 ms
(*po0.05) ISIs (Data from [32]). Right. PD patients recorded before bilateral pallidotomy (inverted red triangles) showed
habituation at 60%, 75%, and 80%, respectively for the three ISIs. After pallidotomy (blue circles), the same patients showed
35%, 35%, and 60%, respectively. The percent habituation differed signiﬁcantly between the post- and pre-surgery results at
the 250 ms and 500 ms ISIs (**po0.01), and were not different from control subjects (black squares) (Data from [33]).
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pedunculopontine nucleus (PPN)
The ﬁrst investigators to stimulate the region of the PPN were
Moruzzi and Magoun [35] to transform the electroencephalo-
gram (EEG) from slow wave activity to fast activity. They used
chloralose-anesthetized or midbrain-transected (decerebrate)
cats and stimulated the region of the mesencephalic reticular
formation. They also performed lesions immediately anterior
to the PPN that eliminated the effects of such stimulation.
These studies typically used stimulation frequencies of
300 Hz, but established that 50 Hz stimulation was close to
the lowest effective frequency. Interestingly, the effects of
stimulation had a latency, typically under 1 s, that is, stimu-
lation was not instantaneous, but effective in inducing high
frequency EEG at short latency.
Many years later, other investigators reported the pre-
sence of a region called the mesencephalic locomotor region
(MLR), stimulation of which in the midbrain-transected
(decebrate) cat, induced controlled locomotion on a moving
treadmill [36]. By controlled locomotion, workers meant that
increasing current levels elicited a walk, then a trot, then a
gallop. Moreover, locomotion entailed alternation of antago-
nists in the same limb, and of agonizts in different limbs.
These parameters are important because they establish a
speciﬁc relation to stepping, rather than a general correlation
with so-called “activity” or “exploration”. The parameters of
stimulation were quite speciﬁc, requiring low current levels
(o100 μA), 40–60 Hz stimulation, and localized to the lateral,
but not the medial, cuneiform nucleus. We investigated this
region and ultimately established that the MLR was not a
locomotion-speciﬁc region, but actually a rhythmogenic area
that overlapped with the histologically identiﬁed PPN, that
basically drove descending projections to induce changes inposture and locomotion [37–39]. Stimulation at high fre-
quency (300 Hz) typically induced reduction in extensor
muscle tone [40], while stimulation at 40–60 Hz induced
locomotion [37–39]. We concluded that the optimal site of
stimulation was in the lateral cuneiform nucleus, and that
stimulation “recruited”, rather than “induced” locomotion,
since it required 1 s of stimulation to have the desired effect
[37–39,41]. It was this line of research that led us to propose
the use of PPN DBS for the treatment of PD.
A recent review considers in detail the reasons why these
parameters are effective for inducing stepping [1], but will not
be considered here. Brieﬂy, beta/gamma oscillations in every
PPN cell are mediated by high threshold, voltage-dependent
N- and P/Q-type calcium channels [42]. We discovered that
every cell in the PPN manifests beta/gamma frequency
oscillations when depolarized using current ramps, but not
when using current steps [42]. This is the only property
shared by every PPN neuron, whether cholinergic, glutama-
tergic, or GABAergic. That is, ramping up current avoided the
activation of potassium channels that would prevent the
membrane from reaching the depolarized levels needed to
activate the high threshold, voltage-dependent N- and P/Q-
type calcium channels essential to beta/gamma frequency
oscillations [42]. This property makes it necessary that PPN
cells be ramped up to reach the depolarizing thresholds for
voltage-dependent calcium channels that are typically
located in the dendrites [43]. Fig. 2 illustrates the properties
of PPN cells that require that stimuli be ramped up, instead of
suddenly turned on, in order to induce intrinsic gamma band
oscillations. Current steps failed to maintain depolarization
of the membrane potential, probably due to potassium
channel activation, while ramps slowly (1 s) depolarize
the membrane potential to activate the high threshold
calcium channels.
Fig. 2 – Manifestation of gamma oscillations in PPN neurons
requires current ramps instead of current steps. Left. Patch
clamp recordings from a PPN neuron in the presence of
synaptic blockers and TTX to record intrinsic membrane
properties. Application of current steps could not maintain
the membrane potential at highly depolarized levels,
preventing beta/gamma oscillations mediated by high
threshold calcium channels to be manifested. Right.
Application of current ramps slowly depolarized the
membrane potential until reaching the threshold of the
calcium channels mediating the oscillations. The window of
activation for this cell was in the 30 mV (black record) to
20 mV (gray record) (Data from [42]).
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locomotion
The RAS is a phylogenetically conserved system that modulates
ﬁght-or-ﬂight responses. During waking, man's ability to detect
predator or prey is essential to survival. Under these circum-
stances, it is not surprising that the RAS can modulate muscle
tone and locomotion. This system is thus intrinsically linked to
the control of the motor system in order to optimize attack or
escape. During REM sleep, the atonia keeps us from acting out
our dreams. In fact, only our diaphragm and eye muscles
appear to be acting out dream content. Therefore, during both
waking and REM sleep, two states modulated by the PPN, the
RAS can inﬂuence muscle tone and locomotion via the same
reticulospinal systems [44]. For example, in a standing indivi-
dual, there is tonic activation of anti-gravity, mainly extensor,
muscles (the same ones inhibited in the atonia of REM sleep).
Before the ﬁrst step can be taken, there must be ﬂexion of the
leg, therefore, there must be a release from standing, or
extensor inhibition, from this postural extensor bias. It should
be noted that the ﬁrst sign of stepping from a standing position
will always be extensor inhibition to unlock the knees, only
then followed by ﬂexion. Extensor inhibition is thus the ﬁrst
action modulated by descending PPN outputs. The question is
whether or not the extensor inhibition is prolonged to induce
postural collapse (as in the cataplexy of narcolepsy), or does it
lead to ﬂexion–extension alternation and locomotion [44].
Outputs from the PPN and perhaps its descending target,
the SubCoeruleus nucleus dorsali (SubCD), activate reticulosp-
inal systems that lead to profound hyperpolarization of
motoneurons, which is the mechanism responsible for the
atonia of REM sleep [45]. Cholinergic projections from the PPN
to the medioventral medulla elicit locomotion [46]. Outputs
from this medullary region in turn activate reticulospinal
systems that lead to the triggering of spinal pattern generators
to induce stepping [37,38,47]. In general, electrical stimulation
of the pontine and medullary reticular formation is known toinduce decreased muscle tone at some sites, while producing
stepping movements at other sites. This suggests the presence
of a heterogeneous, distributed system of reticulospinal motor
control. The required parameters of stimulation for eliciting
these differing effects are important such that instantaneous,
high frequency (4100 Hz) trains (similar to high frequency
bursting activity in the range of ponto-geniculo-occipital (PGO)
burst neurons that may drive the atonia of REM sleep) trigger
pathways which lead to decreased muscle tone, while lower
frequency (40–60 Hz) tonic stimulation leads gradually to the
“recruitment” of locomotor movements [38,41]. Therefore,
given the extensive evidence, it is to be expected that the
PPN, as part of the RAS, should modulate both posture and
locomotion in addition to arousal.5. Stimulation of other regions
The region of the PPN is not the only site stimulated to induce
changes in arousal [44]. Regions aside from the RAS implicated
in the modulation of waking include: (a) the orexin-containing
neurons of the lateral hypothalamus, (b) the cholinergic neu-
rons of the basal forebrain, and (c) the histamine-containing
neurons of the tuberomammillary nucleus. However, it is
important to note the amount of time that stimulation of these
regions takes to induce waking. Why is the latency to induction
of a waking EEG important? The implication is that short
latency effects on waking reﬂect more direct activation of the
cortical EEG, whereas long latency effects reﬂect a circuitous
route for achieving high frequency EEG activity in the cortex.
Typically, stimulation of the RAS, either in the region of the PPN
using electrodes [35,47], or optogenetic methods activating the
locus coeruleus [48], will induce high frequency arousal-related
EEG changes within 1–2 s. However, stimulation of the basal
forebrain induces high frequency EEG but only after 15 s of
stimulation [49], and stimulation of the lateral hypothalamus,
or optogenetically activated orexin neurons, elicits high fre-
quency EEG activity only after 20 s of stimulation [48]. The fact
is that stimulation of the RAS-thalamic pathway elicits cortical
arousal ten times faster than stimulation of the basal forebrain
or lateral hypothalamic/orexin pathways. That is, both the
basal forebrain and hypothalamus need to project elsewhere
to induce a waking EEG, and, as we will see below, neither
region is the ﬁnal common pathway for arousal.
a. Orexin lateral hypothalamic neurons – Some of the sleep
disturbances manifested in PD may be due to loss of
hypocretin cells in this disorder [50]. While much attention
has been paid to hypothalamic neurons in the control of
waking, de Lecea's lab has optogenetically engineered
animals that have rhodopsin cation channels in orexin
and in noradrenergic locus coeruleus (LC) neurons [51].
Their ﬁndings showed that light activation of orexin neu-
rons shows a latency 20 s to induce waking, implying that
its output must travel elsewhere before the animal awa-
kens. When they light activated LC cells, the animals woke
up immediately, within 1–2 s, but if LC was inactivated by
introduction of chloride channels, orexin neuron stimula-
tion failed to awaken the animals. These results suggest
that orexin neurons must ﬁrst affect at least one of their
Fig. 3 – Short latency arousal following RAS stimulation
compared to long latency after basal forebrain or
hypothalamus stimulation. Sagittal diagram of the rodent
brain shows the locations of the basal forebrain (BF), lateral
hypothalamus (LH), locus coeruleus (LC), pedunculopontine
nucleus (PPN), and thalamus (TH). Stimulation of the LC
showed a 1–2 s latency to waking, while stimulation of the
mesencephalic reticular formation near the PPN showed a
similar latency. However, stimulation of the LH exhibited a
20þ s latency, while stimulation of the BF showed a 15 s
latency. Inhibition of the LC showed that stimulation of the
LH was ineffective, suggesting that LH orexin neurons must
activate the RAS in order to have an effect on waking (Data
from [44]).
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waking effect in vivo. That is, the lateral hypothalamic
system may act through the RAS to elicit arousal.
The prolonged latency required to induce arousal after
orexin neuron activation suggests that this region
“recruits” waking but only after prolonged latency. The
result showing that optogenetic inactivation/inhibition of
the LC in advance of activation of optogenetically altered
orexin neurons fails to induce waking [52] suggest that, in
the absence of ascending RAS, speciﬁcally the LC, orexin
cells cannot induce a waking-like EEG. In other words,
descending projections to the RAS may be essential for
these cells to ultimately produce an effect on waking.
Moreover, the role of these neurons is regulated by sleep
deprivation. Optogenetic stimulation experiments found
that sleep deprivation blocks the ability of orexin to
activate its downstream targets and enhance waking
[53], suggesting that these neurons can be kept from
exercising an effect on waking by simple sleep deprivation.
Therefore, rather than a speciﬁc role in arousal, orexin
neurons have been implicated in the integration of motor,
metabolic, circadian, and limbic inputs that can inﬂuence
sleep to wake transitions [54].
b. Basal forebrain neurons- Activation of the basal forebrain
induces low amplitude, high frequency EEG in the cortex
[55]. Recordings in this region showed that most cells were
related to waking and very few related to slow wave sleep
(SWS) [56]. Later studies found that basal forebrain neurons
did indeed ﬁre in relation to both waking and REM sleep
[57]. In addition, lesions of basal forebrain neurons were
found to increase SWS [58]. All of these ﬁndings suggest
that basal forebrain cells help manifest the high frequency
cortical EEG. However, a number of groups have suggested
that this cell group modulates waking via projections to the
brainstem [59–62], and perhaps, also via the thalamus
[62,63]. This suggestion is supported by experiments in
which stimulation of mesopontine cholinergic nuclei in
the brainstem resulted in cortical activation, an effect that
persisted even after lesions of the basal forebrain [64].
Moreover, early studies showed that acute precollicular
transections in which the basal forebrain was anterior to
the transection, eliminate fast activity related to waking
and REM sleep, i.e. the basal forebrain by itself cannot drive
the cortex to maintain gamma band activity in vivo [35,65].
This was conﬁrmed by studies in which transection at the
level of the posterior edge of the inferior colliculus to the
anterior hypothalamus, thus disconnecting the basal fore-
brain and cortex from the brainstem induced profound
coma [65]. Despite the fact that chronic transections did
suggest that the basal forebrain modulates waking to some
extent, the RAS appears to be the ﬁnal common pathway
for induction of the high EEG frequency states of waking
and REM sleep by the basal forebrain.
c. Histamine tuberomammillary neurons- The histamine neurons
of the tuberomammillary nucleus represent the only hista-
minergic cells in the brain. They are located in the posterior
hypothalamus and they have a reciprocal relationship with
ventrolateral preoptic cells [59,60]. Tuberomammillary cells
are inhibited by ventrolateral preoptic cells that promote
sleep [66], and are excited by orexin cells of the lateralhypothalamus [67]. However, tuberomammillary histamine
neurons do not manifest pronounced changes in activity in
relation to high frequency EEG [68]. Moreover, knockout
animals lacking the histamine synthesizing enzyme histi-
dine decarboxylase do not show major changes in cortical
EEG and waking time [69,70]. These authors proposed that
the tuberomammillary system is more related to waking in
novel environments, suggesting a modiﬁed role in arousal.
These ﬁndings collectively imply that the tuberomammil-
lary system is also not a ﬁnal common pathway for arousal.
Fig. 3 outlines the locations of the PPN, locus coeruleus (LC),
lateral hypothalamus, and basal forebrain. Stimulation of the
PPN and LC using electrodes or optogenetic methods induces
arousal or high frequency EEG within 1–2 s. However, stimula-
tion of the lateral hypothalamus or basal forebrain typically
takes 10–20 times longer, and inactivation of the LC prevents
lateral hypothalamus stimulation from inducing arousal. Basi-
cally, while the lateral hypothalamus, basal forebrain, and
tuberomammillary systems modulate waking, they are not
primary drivers of arousal.6. PPN deep brain stimulation (DBS)
DBS for the treatment of basal ganglia disorders is most often
used in the subthalamic region and internal pallidum, but these
will not be addressed here. As far as PPN DBS is concerned, early
studies focused on PD patients who presented with axial
symptoms and gait disturbances [71], with subsequent studies
using increasingly sophisticated localization and visualization
methods [72–74]. Most patients showed improvements in gait
using stimulation at 15 and 25 Hz [75], while stimulation at 50
and 70 Hz showed improvements in falls [76]. Sleep patterns
were improved by stimulation at 10 and 25 Hz [77,78], while sleep
S l e e p S c i e n c e 8 ( 2 0 1 5 ) 1 5 3 – 1 6 1158scores and executive function were improved by stimulation at
25 Hz [79]. Double-blind studies established that bilateral stimu-
lation was better than unilateral stimulation at 20–35 Hz in
improving reaction time, fall scores, and gait [80,81]. Presumably,
the continuous stimulation used during DBS helps maintain
beta/gamma band activity in the PPN, but does not produce
hyperarousal because the system is characteristically rapidly
habituating. That is, the phasic function of the RAS is not
ampliﬁed. That may be why continuous PPN DBS does not
produce undesirable arousal side effects, and may in fact help
stabilize PPN output. Thus, it is possible that continuous PPN DBS
provides a persistent signal, regulating and stabilizing the
circuits at physiological (gamma band) frequencies [1]. This helps
maintain waking and awareness, thereby also improving the
tonic function of the RAS. It would be interesting to determine if
PPN stimulation at 40–60 Hz could be used to upregulate PPN
output to restore arousal levels in disorders such as coma or
reduced alertness. It should also be noted that PPN DBS could be
used to downregulate PPN output if so desired, perhaps by
applying higher frequencies such as 100 Hz or higher. It would
also be interesting to determine if continuous high frequency
stimulation could be used to decrease hyperarousal, or alleviate
symptoms of excessive arousal. The P50 potential, as a measure
of level of arousal and sensory gating, could be used to
determine the effects of DBS, and if such treatment corrects
any increases in amplitude or decreases in habituation.
Interestingly, DBS in the medial or intralaminar thalamus is
being used with great success for the treatment of Tourette's
syndrome [82,83]. One side effect of intralaminar thalamus DBS
for Tourette's syndrome is profound fatigue. The parameters of
stimulation typically include 24 h stimulation at high frequen-
cies (4100 Hz). This side effect may respond to decreased
frequency of stimulation (e.g. 40–60 Hz) and for 20/24 h sche-
dules (Visser-Vandewalle, personal communication). That is,
stimulation at frequencies and schedules closer to those used
for PPN DBS may help prevent the fatigue manifested.7. Conclusion
While the use of PPN DBS is becoming more common, there is
still much testing to be performed before it can become clinical
routine. However, the foregoing should make it evident that
optimal outcomes may ensue from using stimulation para-
meters that take advantage of novel information on the
physiology of PPN cells. That is, stimulation at the natural
frequency of PPN cells (20–60 Hz) is likely to recruit beta/gamma
band intrinsic membrane oscillations that are maintained by
the continuous application of PPN DBS. Both ascending arousal
and descending motor control projections from the PPN are
thus optimally activated to normalize PPN outputs. In the
implementation of PPN DBS, we should determine its effects
on wake/sleep cycles by performing sleep studies before and
after implantation. One study performed sleep measures and
found that PPN DBS improved not only nighttime sleep, but also
daytime sleepiness [84]. If PPN DBS can normalize wake/sleep
characteristics, then the technique can be determined to have a
positive outcome on wake/sleep dysregulation in this disorder.
In PD patients followed longitudinally, delta and theta power
increased while higher frequencies, including gamma,decreased, and these changes correlated with cognitive decline
[85]. Determining the effects of PPN DBS on gamma band
power, but especially on gamma band maintenance, would be
very important for assessing the beneﬁcial effects of PPN
stimulation on higher functions. A number of neurological
and psychiatric disorders are also characterized by interrupted
or decreased gamma band activity [39,44].
There is some information that PPN DBS may improve
cognitive function [86], and that low frequency stimulation (5–
30 Hz) may improve executive and higher functions [73], but this
issue needs further elucidation. Lesions of the PPN disturb
attention, executive function and working memory [87], there-
fore, it should be expected that PPN DBS may beneﬁcially affect
higher functions using the appropriate parameters of stimula-
tion. In addition, the PPN has been proposed to participate in the
process of preconscious awareness, the mechanism that allows
us to evaluate the world around us on a continuous basis [44].
This process is embedded in the formulation of our perceptions
and actions, and modulates higher-level beta/gamma processing
through its projections to the intralaminar thalamus, basal
ganglia, hypothalamus, and basal forebrain. That is why it affects
functions as disparate as waking and REM sleep, mood and
perception, and homeostatic regulation. The effects of PPN DBS
also need to be studied for potential modulation of this essential
survival mechanism, preconscious awareness.Acknowledgments
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